Literature DB >> 29700011

An Investigation of Drug-Drug Interaction Alert Overrides at a Pediatric Hospital.

Kate Humphrey1, Maria Jorina2, Marvin Harper3, Brenda Dodson4, Seung-Yeon Kim5, Al Ozonoff2.   

Abstract

OBJECTIVES: Drug-drug interactions (DDIs) can result in patient harm. DDI alerts are intended to help prevent harm; when the majority of alerts presented to providers are being overridden, their value is diminished. Our objective was to evaluate the overall rates of DDI alert overrides and how rates varied by specialty, clinician type, and patient complexity.
METHODS: A retrospective study of DDI alert overrides that occurred during 2012 and 2013 within the inpatient setting described at the medication-, hospital-, provider-, and patient encounter-specific levels was performed at an urban, quaternary-care, pediatric hospital.
RESULTS: There were >41 000 DDI alerts presented to clinicians; ∼90% were overridden. The 5 DDI pairs that were most frequently presented and overridden included the following: potassium chloride-spironolactone, methadone-ondansetron, ketorolac-ibuprofen, cyclosporine-fluconazole, and potassium chloride-enalapril, each with an alert override rate of ≥0.89. Override rates across provider groups ranged between 0.84 and 0.97. In general, patients with high complexity had a higher frequency of alert overrides, but the rates of alert overrides for each DDI pairing did not differ significantly.
CONCLUSIONS: High rates of DDI alert overrides occur across medications, provider groups, and patient encounters. Methods to decrease DDI alerts which are likely to be overridden exist, but it is also clear that more robust and intelligent tools are needed. Characteristics exist at the medication, hospital, provider, and patient levels that can be used to help specialize and enhance information transmission.
Copyright © 2018 by the American Academy of Pediatrics.

Entities:  

Year:  2018        PMID: 29700011     DOI: 10.1542/hpeds.2017-0124

Source DB:  PubMed          Journal:  Hosp Pediatr        ISSN: 2154-1671


  4 in total

1.  Capsule Commentary on Wright et. al.: Reduced Effectiveness of Interruptive Drug-Drug Interaction Alerts After Conversion to a Commercial Electronic Health Record.

Authors:  Ellen E Sarcone
Journal:  J Gen Intern Med       Date:  2018-11       Impact factor: 5.128

2.  Reducing Interruptive Alert Burden Using Quality Improvement Methodology.

Authors:  Juan D Chaparro; Cory Hussain; Jennifer A Lee; Jessica Hehmeyer; Manjusri Nguyen; Jeffrey Hoffman
Journal:  Appl Clin Inform       Date:  2020-01-15       Impact factor: 2.342

3.  Prevalence of Clinically Significant Drug-Drug Interactions Across US Children's Hospitals.

Authors:  James W Antoon; Matt Hall; Alison Herndon; Alison Carroll; My-Linh Ngo; Katherine L Freundlich; Justine C Stassun; Patricia Frost; David P Johnson; Swati B Chokshi; Charlotte M Brown; Whitney L Browning; James A Feinstein; Carlos G Grijalva; Derek J Williams
Journal:  Pediatrics       Date:  2020-10-09       Impact factor: 7.124

Review 4.  Clinical Decision Support Stewardship: Best Practices and Techniques to Monitor and Improve Interruptive Alerts.

Authors:  Juan D Chaparro; Jonathan M Beus; Adam C Dziorny; Philip A Hagedorn; Sean Hernandez; Swaminathan Kandaswamy; Eric S Kirkendall; Allison B McCoy; Naveen Muthu; Evan W Orenstein
Journal:  Appl Clin Inform       Date:  2022-05-25       Impact factor: 2.762

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.